Haemonchus Contortus ABC Transporters Linked to Macrocyclic
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Gastrointestinal Helminthic Parasites of Habituated Wild Chimpanzees
Aus dem Institut für Parasitologie und Tropenveterinärmedizin des Fachbereichs Veterinärmedizin der Freien Universität Berlin Gastrointestinal helminthic parasites of habituated wild chimpanzees (Pan troglodytes verus) in the Taï NP, Côte d’Ivoire − including characterization of cultured helminth developmental stages using genetic markers Inaugural-Dissertation zur Erlangung des Grades eines Doktors der Veterinärmedizin an der Freien Universität Berlin vorgelegt von Sonja Metzger Tierärztin aus München Berlin 2014 Journal-Nr.: 3727 Gedruckt mit Genehmigung des Fachbereichs Veterinärmedizin der Freien Universität Berlin Dekan: Univ.-Prof. Dr. Jürgen Zentek Erster Gutachter: Univ.-Prof. Dr. Georg von Samson-Himmelstjerna Zweiter Gutachter: Univ.-Prof. Dr. Heribert Hofer Dritter Gutachter: Univ.-Prof. Dr. Achim Gruber Deskriptoren (nach CAB-Thesaurus): chimpanzees, helminths, host parasite relationships, fecal examination, characterization, developmental stages, ribosomal RNA, mitochondrial DNA Tag der Promotion: 10.06.2015 Contents I INTRODUCTION ---------------------------------------------------- 1- 4 I.1 Background 1- 3 I.2 Study objectives 4 II LITERATURE OVERVIEW --------------------------------------- 5- 37 II.1 Taï National Park 5- 7 II.1.1 Location and climate 5- 6 II.1.2 Vegetation and fauna 6 II.1.3 Human pressure and impact on the park 7 II.2 Chimpanzees 7- 12 II.2.1 Status 7 II.2.2 Group sizes and composition 7- 9 II.2.3 Territories and ranging behavior 9 II.2.4 Diet and hunting behavior 9- 10 II.2.5 Contact with humans 10 II.2.6 -
ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential
pharmaceuticals Review ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential Subrata Deb * , Anthony Allen Reeves, Robert Hopefl and Rebecca Bejusca Department of Pharmaceutical Sciences, College of Pharmacy, Larkin University, Miami, FL 33169, USA; [email protected] (A.A.R.); [email protected] (R.H.); [email protected] (R.B.) * Correspondence: [email protected]; Tel.: +224-310-7870 Abstract: On 11 March 2020, the World Health Organization (WHO) classified the Coronavirus Disease 2019 (COVID-19) as a global pandemic, which tested healthcare systems, administrations, and treatment ingenuity across the world. COVID-19 is caused by the novel beta coronavirus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Since the inception of the pandemic, treatment options have been either limited or ineffective. Remdesivir, a drug originally designed to be used for Ebola virus, has antiviral activity against SARS-CoV-2 and has been included in the COVID-19 treatment regimens. Remdesivir is an adenosine nucleotide analog prodrug that is metabolically activated to a nucleoside triphosphate metabolite (GS-443902). The active nucleoside triphosphate metabolite is incorporated into the SARS-CoV-2 RNA viral chains, preventing its replication. The lack of reported drug development and characterization studies with remdesivir in public domain has created a void where information on the absorption, distribution, metabolism, elimination (ADME) properties, pharmacokinetics (PK), or drug-drug interaction (DDI) is limited. By Citation: Deb, S.; Reeves, A.A.; understanding these properties, clinicians can prevent subtherapeutic and supratherapeutic levels of Hopefl, R.; Bejusca, R. ADME and remdesivir and thus avoid further complications in COVID-19 patients. Remdesivir is metabolized Pharmacokinetic Properties of by both cytochrome P450 (CYP) and non-CYP enzymes such as carboxylesterases. -
The Identification of Haemonchus Species and Diagnosis of Haemonchosis
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by DigitalCommons@University of Nebraska University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln U.S. Department of Agriculture: Agricultural Publications from USDA-ARS / UNL Faculty Research Service, Lincoln, Nebraska 2016 The Identification of Haemonchus Species and Diagnosis of Haemonchosis Dante Zarlenga E.P. Hoberg W. Tuo Follow this and additional works at: https://digitalcommons.unl.edu/usdaarsfacpub This Article is brought to you for free and open access by the U.S. Department of Agriculture: Agricultural Research Service, Lincoln, Nebraska at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Publications from USDA-ARS / UNL Faculty by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. CHAPTER FIVE The Identification of Haemonchus Species and Diagnosis of Haemonchosis D.S. Zarlenga1, E.P. Hoberg, W. Tuo USDA, Agricultural Research Service, Beltsville, MD, United States 1Corresponding author: E-mail: [email protected] Contents 1. Introduction 146 2. Morphological Approaches for Identifying Haemonchus contortus 147 2.1 Morphology; the gold standard 147 2.1.1 Identification of adult worms 148 2.1.2 Identification of infective third-stage larvae 150 2.1.3 Identification of parasitic fourth-stage larvae 152 2.1.4 Identification of eggs 152 3. Molecular Methods for Identifying Haemonchus 155 3.1 Haemonchus contortus, Haemonchus placei or both? 155 3.2 Traditional PCR 157 3.3 Real-time PCR 159 3.4 The next generation 162 3.4.1 Loop-mediated isothermal amplification 162 3.4.2 Metagenomics and pyrosequencing 163 4. -
Tuesday June 2 Wednesday June 3
Tuesday June 2 14:00- Registration 18:30 19:30 Welcome reception Wednesday June 3 08:00- Registration 09:00 09:00- Welcome and Introduction 09:15 09:15- Targeting Ebola Chair: Steven Kern 10:45 09:15- Conducting clinical trials in challenging Steven Kern 09:30 environments 09:30- France Estimating an effective dose for a repurposed 09:55 Mentré drug to treat Ebola: the case of favipiravir Estimating an effective dose for a new drug to 09:55- Matthias treat Ebola with incomplete information: the 10:20 Machacek case of Zmapp 10:20- An Adaptive Platform Trial for Ebola: Scott Berry 10:45 Application to Future Epidemics 10:45- Coffee break, Poster and Software session I 12:15 Posters in Group I (with poster numbers starting with I-) are accompanied by their presenter 12:15- Diabetes Chair: IñakiTrocóniz 12:55 Page | 1 12:15- Roberto A model of glucose clearance to improve the 12:35 Bizzotto description of glucose homeostasis A longitudinal HbA1c model elucidates genes 12:35- Rada Savic linked to disease progression on metformin 12:55 therapy 12:55- Lunch 14:25 On the 20th anniversary of 'Nonlinear 14:25- Chair: France models for repeated measurement 15:15 Mentré data' 14:25- David Why write a book in 1995 on nonlinear mixed 14:50 Giltinan effects modeling? 14:50- Marie Subsequent developments in nonlinear mixed 15:15 Davidian effects modeling 15:15- Tea break, Poster and Software session II 16:40 Posters in Group II (with poster numbers starting with II-) are accompanied by their presenter 16:40- Other diseases Chair: Ana Ruiz 17:40 José -
Anthelmintic Resistance of Ostertagia Ostertagi and Cooperia Oncophora to Macrocyclic Lactones in Cattle from the Western United States
Veterinary Parasitology 170 (2010) 224–229 Contents lists available at ScienceDirect Veterinary Parasitology journal homepage: www.elsevier.com/locate/vetpar Anthelmintic resistance of Ostertagia ostertagi and Cooperia oncophora to macrocyclic lactones in cattle from the western United States M.D. Edmonds, E.G. Johnson, J.D. Edmonds ∗ Johnson Research LLC, 24007 Highway 20-26, Parma, ID, 83660, USA article info abstract Article history: In June 2008, 122 yearling heifers with a history of anthelmintic resistance were obtained Received 15 October 2009 from pastures in northern California and transported to a dry lot facility in southwest- Received in revised form 28 January 2010 ern Idaho, USA. Fifty heifers with the highest fecal egg counts were selected for study Accepted 24 February 2010 enrollment. Candidates were equally randomized to treatment with either injectable iver- mectin (Ivomec®, Merial, 0.2 mg kg−1 BW), injectable moxidectin (Cydectin®, Fort Dodge, Keywords: 0.2 mg kg−1 BW), oral fenbendazole (Safe-Guard®, Intervet, 5.0 mg kg−1 BW), oral oxfenda- Anthelmintic resistance zole (Synanthic®, Fort Dodge, 4.5 mg kg−1 BW), or saline. At 14 days post-treatment, Cattle Bovine nematodes were recovered from the abomasum, small intestine, and large intestine. Par- Nematodes asitism was confirmed in the control group when 10/10 animals were infected with Efficacy adult Ostertagia ostertagi and 9/10 animals with both developing and early L4 stages of Cooperia O. ostertagi. Similarly, 9/10 animals were parasitized with adult Cooperia spp. Fenbenda- Ostertagia zole and oxfendazole efficacy verses controls were >90% against adult Cooperia spp., while moxidectin caused an 88% parasite reduction post-treatment (P < 0.05). -
CAS Number Index
2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5 -
Vitro Exposure to Ivermectin and Levamisole on the Expression Patterns of ABC Transporters in Haemonchus Contortus Larvae
International Journal for Parasitology: Drugs and Drug Resistance 6 (2016) 103e115 Contents lists available at ScienceDirect International Journal for Parasitology: Drugs and Drug Resistance journal homepage: www.elsevier.com/locate/ijppaw Effects of in vitro exposure to ivermectin and levamisole on the expression patterns of ABC transporters in Haemonchus contortus larvae * Ali Raza a, b, Steven R. Kopp b, Neil H. Bagnall a, Abdul Jabbar c, Andrew C. Kotze a, a CSIRO Agriculture, Queensland Bioscience Precinct, University of Queensland, Brisbane, Australia b School of Veterinary Science, University of Queensland, Gatton, Australia c Faculty of Veterinary and Agricultural Sciences, University of Melbourne, Werribee, Victoria, Australia article info abstract Article history: This study investigated the interaction of ATP binding cassette (ABC) transport proteins with ivermectin Received 15 October 2015 (IVM) and levamisole (LEV) in larvae of susceptible and resistant isolates of Haemonchus contortus in vitro Received in revised form by measuring transcription patterns following exposure to these anthelmintics. Furthermore, we studied 21 March 2016 the consequences of drug exposure by measuring the sensitivity of L to subsequent exposure to higher Accepted 22 March 2016 3 drug concentrations using larval migration assays. The most highly transcribed transporter genes in both Available online 23 March 2016 susceptible and resistant L3 were pgp-9.3, abcf-1, mrp-5, abcf-2, pgp-3, and pgp-10. The resistant isolate showed significantly higher transcription of pgp-1, pgp-9.1 and pgp-9.2 compared to the susceptible Keywords: fi ABC transporters isolate. Five P-gp genes and the haf-6 gene showed signi cantly higher transcription (up to 12.6-fold) fi Anthelmintics after 3 h exposure to IVM in the resistant isolate. -
Current Therapeutic Applications and Pharmacokinetic Modulations of Ivermectin
Veterinary World, EISSN: 2231-0916 REVIEW ARTICLE Available at www.veterinaryworld.org/Vol.12/August-2019/5.pdf Open Access Current therapeutic applications and pharmacokinetic modulations of ivermectin Khan Sharun1, T. S. Shyamkumar2, V. A. Aneesha2, Kuldeep Dhama3, Abhijit Motiram Pawde1 and Amar Pal1 1. Division of Surgery, ICAR-Indian Veterinary Research Institute, Bareilly, Uttar Pradesh, India; 2. Division of Pharmacology and Toxicology, ICAR-Indian Veterinary Research Institute, Bareilly, Uttar Pradesh, India; 3. Division of Pathology, ICAR-Indian Veterinary Research Institute, Bareilly, Uttar Pradesh, India. Corresponding author: Khan Sharun, e-mail: [email protected] Co-authors: TSS: [email protected], VAA: [email protected], KD: [email protected], AMP: [email protected], AP: [email protected] Received: 17-05-2019, Accepted: 29-06-2019, Published online: 08-08-2019 doi: 10.14202/vetworld.2019.1204-1211 How to cite this article: Sharun K, Shyamkumar TS, Aneesha VA, Dhama K, Pawde AM, Pal A (2019) Current therapeutic applications and pharmacokinetic modulations of ivermectin, Veterinary World, 12(8): 1204-1211. Abstract Ivermectin is considered to be a wonder drug due to its broad-spectrum antiparasitic activity against both ectoparasites and endoparasites (under class of endectocide) and has multiple applications in both veterinary and human medicine. In particular, ivermectin is commonly used in the treatment of different kinds of infections and infestations. By altering the vehicles used in the formulations, the pharmacokinetic properties of different ivermectin preparations can be altered. Since its development, various vehicles have been evaluated to assess the efficacy, safety, and therapeutic systemic concentrations of ivermectin in different species. A subcutaneous route of administration is preferred over a topical or an oral route for ivermectin due to superior bioavailability. -
Nematodirus Spathiger of Small Ruminants Guang-Hui Zhao1*†, Yan-Qing Jia1†, Wen-Yu Cheng1, Wen Zhao1, Qing-Qing Bian1 and Guo-Hua Liu2*
Zhao et al. Parasites & Vectors 2014, 7:319 http://www.parasitesandvectors.com/content/7/1/319 RESEARCH Open Access Characterization of the complete mitochondrial genomes of Nematodirus oiratianus and Nematodirus spathiger of small ruminants Guang-Hui Zhao1*†, Yan-Qing Jia1†, Wen-Yu Cheng1, Wen Zhao1, Qing-Qing Bian1 and Guo-Hua Liu2* Abstract Background: Nematodirus spp. are among the most common nematodes of ruminants worldwide. N. oiratianus and N. spathiger are distributed worldwide as highly prevalent gastrointestinal nematodes, which cause emerging health problems and economic losses. Accurate identification of Nematodirus species is essential to develop effective control strategies for Nematodirus infection in ruminants. Mitochondrial DNA (mtDNA) could provide powerful genetic markers for identifying these closely related species and resolving phylogenetic relationships at different taxonomic levels. Methods: In the present study, the complete mitochondrial (mt) genomes of N. oiratianus and N. spathiger from small ruminants in China were obtained using Long-range PCR and sequencing. Results: The complete mt genomes of N. oiratianus and N. spathiger were 13,765 bp and 13,519 bp in length, respectively. Both mt genomes were circular and consisted of 36 genes, including 12 genes encoding proteins, 2 genes encoding rRNA, and 22 genes encoding tRNA. Phylogenetic analyses based on the concatenated amino acid sequence data of all 12 protein-coding genes by Bayesian inference (BI), Maximum likelihood (ML) and Maximum parsimony (MP) showed that the two Nematodirus species (Molineidae) were closely related to Dictyocaulidae. Conclusions: The availability of the complete mtDNA sequences of N. oiratianus and N. spathiger not only provides new mtDNA sources for a better understanding of nematode mt genomics and phylogeny, but also provides novel and useful genetic markers for studying diagnosis, population genetics and molecular epidemiology of Nematodirus spp. -
Parasitology Group Annual Review of Literature and Horizon Scanning Report 2018
APHA Parasitology Group Annual Review of Literature and Horizon Scanning Report 2018 Published: November 2019 November 2019 © Crown copyright 2018 You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v.3. To view this licence visit www.nationalarchives.gov.uk/doc/open-government-licence/version/3/ or email [email protected] This publication is available at www.gov.uk/government/publications Any enquiries regarding this publication should be sent to us at [email protected] Year of publication: 2019 The Animal and Plant Health Agency (APHA) is an executive agency of the Department for Environment, Food & Rural Affairs, and also works on behalf of the Scottish Government and Welsh Government. November 2019 Contents Summary ............................................................................................................................. 1 Fasciola hepatica ............................................................................................................. 1 Rumen fluke (Calicophoron daubneyi) ............................................................................. 2 Parasitic gastro-enteritis (PGE) ........................................................................................ 2 Anthelmintic resistance .................................................................................................... 4 Cestodes ......................................................................................................................... -
P-Glycoprotein Drug Transporters in the Parasitic Nematodes Toxocara Canis and Parascaris
Iowa State University Capstones, Theses and Graduate Theses and Dissertations Dissertations 2019 P-glycoprotein drug transporters in the parasitic nematodes Toxocara canis and Parascaris Jeba Rose Jennifer Jesudoss Chelladurai Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/etd Part of the Parasitology Commons, and the Veterinary Medicine Commons Recommended Citation Jesudoss Chelladurai, Jeba Rose Jennifer, "P-glycoprotein drug transporters in the parasitic nematodes Toxocara canis and Parascaris" (2019). Graduate Theses and Dissertations. 17707. https://lib.dr.iastate.edu/etd/17707 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. P-glycoprotein drug transporters in the parasitic nematodes Toxocara canis and Parascaris by Jeba Rose Jennifer Jesudoss Chelladurai A dissertation submitted to the graduate faculty in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Major: Veterinary Pathology (Veterinary Parasitology) Program of Study Committee: Matthew T. Brewer, Major Professor Douglas E. Jones Richard J. Martin Jodi D. Smith Tomislav Jelesijevic The student author, whose presentation of the scholarship herein was approved by the program of study committee, is solely responsible for the content of this dissertation. The Graduate College will ensure this dissertation is globally accessible and will not permit alterations after a degree is conferred. Iowa State University Ames, Iowa 2019 Copyright © Jeba Rose Jennifer Jesudoss Chelladurai, 2019. -
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .